Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03WEX
|
|||
| Former ID |
DNCL003062
|
|||
| Drug Name |
Vortioxetine
|
|||
| Synonyms |
VORTIOXETINE; 508233-74-7; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; UNII-3O2K1S3WQV; 3O2K1S3WQV; CHEBI:76016; Trintellix; 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine; Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; Brintellix (TN); 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine; 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; CHEMBL2204360; 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine; Lu-AA21004
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Approved | [1], [2] | |
| Mood disorder [ICD-11: 6A60-6E23] | Phase 3 | [3] | ||
| Company |
Lundbeck; Takeda Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N2S
|
|||
| Canonical SMILES |
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C
|
|||
| InChI |
1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
|
|||
| InChIKey |
YQNWZWMKLDQSAC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 508233-74-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14942974, 24232104, 46062622, 74967215, 134339122, 135268324, 135626902, 137031414, 141291936, 160676538, 160874200, 162224457, 163349926, 163409417, 163847660, 164347389, 164777223, 172919848, 175266271, 178103923, 185968494, 187072019, 189628085, 198993777, 210024065, 210275229, 210280867, 223595856, 224449304, 226587298, 242073286, 244850411, 249828940, 250182630, 251899315, 252055744, 252090010, 252313288, 252499412
|
|||
| ChEBI ID |
CHEBI:76016
|
|||
| ADReCS Drug ID | BADD_D02371 ; BADD_D02372 | |||
| SuperDrug ATC ID |
N06AX26
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serotonin transporter (SERT) | Target Info | Inhibitor | [2], [2], [3], [4] |
| KEGG Pathway | Serotonergic synapse | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | 5HT1 type receptor mediated signaling pathway | |||
| 5HT2 type receptor mediated signaling pathway | ||||
| 5HT3 type receptor mediated signaling pathway | ||||
| 5HT4 type receptor mediated signaling pathway | ||||
| WikiPathways | Monoamine Transport | |||
| SIDS Susceptibility Pathways | ||||
| NRF2 pathway | ||||
| Synaptic Vesicle Pathway | ||||
| Serotonin Transporter Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7351). | |||
| REF 2 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | |||
| REF 3 | Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013 Apr;105:41-50. | |||
| REF 4 | A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.